Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.34 |
| ▸ | FYN | P06241 | 6/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | TRPC6 | Q9Y210 | 4/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31000263 | 0.88 | FYN (0.32) | FYNLRRK2 | |
| SCHEMBL31000244 | 0.85 | TRPC6 (0.31) | TRPC6 | |
| SCHEMBL31000298 | 0.84 | TYRO3 (0.33) | — | |
| SCHEMBL24975689 | 0.84 | PDE10A (0.36) | PDE10AFYNPDGFRBPDGFRATRPC6 | |
| SCHEMBL31000219 | 0.83 | — | — | |
| SCHEMBL31000271 | 0.80 | CNR2 (0.34) | — | |
| SCHEMBL31000264 | 0.74 | — | — | |
| SCHEMBL31000231 | 0.74 | NRAS (0.34) | FYNTRPC6CDK2PDE4D | |
| SCHEMBL31000261 | 0.74 | IGF1R (0.38) | CDK2 | |
| SCHEMBL24542495 | 0.72 | FLT3 (0.42) | FYNPDGFRBPDGFRAPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658659-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | Children's Hospital Medical Center (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250154144-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDRENS HOSPITAL MED CT (US) | 2025-05-15 | — | — | US | disclosed |
| CN-118613480-A | Polycyclic IRAK and FLT3 inhibiting compounds and uses thereof | 儿童医院医学中心 | 2024-09-06 | — | — | CN | disclosed |
| WO-2024163764-A2 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2024-08-08 | — | — | WO | disclosed |
| WO-2023009833-A9 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023009833-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154144-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK1, IRAK3 | PDE10A 1749/4885FYN 301/4885PDGFRB 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.